Cover Image
市場調查報告書

癡呆症:開發平台分析

Dementia - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 245960
出版日期 內容資訊 英文 219 Pages
訂單完成後即時交付
價格
Back to Top
癡呆症:開發平台分析 Dementia - Pipeline Review, H1 2017
出版日期: 2017年03月15日 內容資訊: 英文 219 Pages
簡介

所謂癡呆症是指思考力·記憶力·推理力等日常生活機能相關的重要精神機能受損狀態。主要的症狀有記憶力衰退和妄想、興奮、人格變化、調整·運動能力、障礙等。致病的危險因子有年齡和抽煙、肥胖症、高血壓、發炎、心血管疾病等。

本報告提供全球各國治療癡呆症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

癡呆症概要

治療藥的開發

  • 癡呆症開發中產品:概要
  • 癡呆症開發中產品:比較分析

各企業開發中的癡呆症治療藥

大學/研究機關研究中的癡呆症治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

癡呆症治療藥:開發中的產品的一覽(各企業)

癡呆症治療藥:研究中的產品的一覽(大學/研究機關別)

癡呆症開發治療藥的企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Alector LLC
  • AlzProtect SAS
  • Amarantus Bioscience Holdings, Inc.
  • Axon Neuroscience SE
  • Axovant Sciences Ltd.
  • BioArctic Neuroscience AB
  • Biogen, Inc.
  • Biotie Therapies Corp.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • Daewoong Pharmaceutical Co., Ltd.
  • Eisai
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • Heptares Therapeutics Limited
  • Hyundai Pharmaceutical Co., Ltd.
  • Ildong Pharmaceutical Co., Ltd.
  • Immungenetics AG
  • ImStar Therapeutics Inc.
  • Integrative Research Laboratories Sweden AB
  • Intellect Neurosciences, Inc.
  • Intra-Cellular Therapies, Inc.
  • MediPost Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Neurimmune Holding AG
  • Neurodyn Inc.
  • Oryzon Genomics S.A.
  • Ovid Therapeutics Inc.
  • P2D Bioscience
  • Pacific Northwest Biotechnology, LLC
  • Pivot Pharmaceuticals Inc
  • Sinil Pharmaceutical Co., Ltd
  • Stelic Institute & Co., Inc.
  • 大日本住友製藥
  • Sylentis S.A.U.
  • TauRx Therapeutics Ltd.
  • WhanIn Pharmaceutical Co., Ltd.

癡呆症:治療藥的評估

  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AADvac-1
  • Antisense Oligonucleotides to Inhibit microRNA for Neurology
  • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia
  • AVCRI-104P3
  • AZP-2006
  • BAN-0805
  • BI-409306
  • CB-2233
  • CB-8411
  • choline alfoscerate SR
  • CPC-201
  • CPC-252
  • D-217
  • dehydroevodiamine hydrochloride
  • Drugs for Dementia
  • Drugs to Agonize c-MET for Dementia
  • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment
  • DWJ-1365
  • E-2609
  • eltoprazine
  • encenicline hydrochloride
  • FRM-0334
  • GIBH-130
  • Gln-1062
  • GTC-6000
  • gugulipid
  • HOB-075
  • HTL-18318
  • IRL-752
  • ITI-007
  • KR-12
  • levetiracetam
  • LH-026
  • LUAF-20513
  • MM-201
  • Monoclonal Antibodies for Dementia and Alzheimer's Disease
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders
  • NAT
  • nelotanserin
  • Neurostem
  • NI-205
  • NI-308
  • NNC-269100
  • NP-001
  • OG-635
  • ORY-2001
  • OV-201
  • P-003
  • PD-2015
  • PD-2016
  • PD-2024
  • PD-2244
  • PD-61W3
  • Peptide to Inhibit BACE for Cerebropathy and Dementia
  • PST-900
  • RVT-101
  • salicylamine
  • SIN-1502
  • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders
  • Small Molecule to Activate LPL for CNS and Metabolic Disorders
  • Small Molecule to Inhibit Glycogene 5 for Dementia
  • Small Molecules for Frontotemporal Dementia
  • Small Molecules for Ophthalmology and CNS Disorders
  • Small Molecules to Agonize HGFR for CNS Disorders
  • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Lewy Body Dementia and Parkinson's Disease Dementia
  • Small Molecules to Inhibit TANA for ALS, Dementia and Alzheimer's Disease
  • SND-14
  • SYN-120
  • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders
  • TAK-070
  • TauC-3
  • TPI-287
  • TRx-0237
  • TTT-3002
  • WIB-1001C
  • zonisamide

癡呆症治療藥:開發中產品的最新趨勢

癡呆症治療藥:開發暫停的產品

癡呆症治療藥:開發中止的產品

癡呆症相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9056IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia - Pipeline Review, H1 2017, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 17, 33, 12 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 6
  • List of Figures 7
  • Introduction 9
  • Global Markets Direct Report Coverage 9
  • Dementia - Overview 10
  • Dementia - Therapeutics Development 11
  • Pipeline Overview 11
  • Pipeline by Companies 12
  • Pipeline by Universities/Institutes 17
  • Products under Development by Companies 19
  • Products under Development by Universities/Institutes 24
  • Dementia - Therapeutics Assessment 25
  • Assessment by Target 25
  • Assessment by Mechanism of Action 29
  • Assessment by Route of Administration 32
  • Assessment by Molecule Type 34
  • Dementia - Companies Involved in Therapeutics Development 36
  • Acorda Therapeutics Inc 36
  • Actinogen Medical Ltd 36
  • Adamas Pharmaceuticals Inc 37
  • AgeneBio Inc 37
  • Alector LLC 38
  • Allergan Plc 38
  • AlzProtect SAS 39
  • Amarantus Bioscience Holdings Inc 39
  • Anavex Life Sciences Corp 40
  • Asceneuron SA 40
  • Axon Neuroscience SE 41
  • Axovant Sciences Ltd. 41
  • BioArtic AB 42
  • Biogen Inc 42
  • Boehringer Ingelheim GmbH 43
  • Cortice Biosciences Inc 43
  • Daewoong Pharmaceutical Co Ltd 44
  • Echo Pharmaceuticals BV 44
  • Eisai Co Ltd 45
  • Eli Lilly and Company 45
  • H. Lundbeck A/S 46
  • Heptares Therapeutics Ltd 47
  • HSRx Group 47
  • Hyundai Pharmaceutical Co Ltd 48
  • Ildong Pharmaceutical Co Ltd 48
  • Immungenetics AG 49
  • ImStar Therapeutics Inc 49
  • Integrative Research Laboratories Sweden AB 50
  • Intellect Neurosciences Inc 50
  • INVENT Pharmaceuticals Inc 51
  • Ironwood Pharmaceuticals Inc 51
  • M3 Biotechnology Inc 52
  • MediPost Co Ltd 52
  • Neuraltus Pharmaceuticals Inc 53
  • Neurimmune Holding AG 53
  • Neuropore Therapies Inc 54
  • NsGene A/S 54
  • Oryzon Genomics SA 55
  • P2D Bioscience 55
  • Pacific Northwest Biotechnology LLC 56
  • Pharmasum Therapeutics AS 56
  • Prana Biotechnology Ltd 57
  • Sage Therapeutics Inc 57
  • Sinil Pharmaceutical Co Ltd 58
  • Stelic Institute & Co Inc 58
  • Stemedica Cell Technologies Inc 59
  • Sumitomo Dainippon Pharma Co Ltd 59
  • Suven Life Sciences Ltd 60
  • Sylentis SAU 60
  • TauRx Therapeutics Ltd 61
  • Voyager Therapeutics Inc 61
  • WhanIn Pharmaceutical Co Ltd 62
  • Zhejiang Hisun Pharmaceutical Co Ltd 62
  • Dementia - Drug Profiles 63
  • (donepezil hydrochloride + glycopyrrolate) - Drug Profile 63
  • (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile 64
  • (donepezil hydrochloride + solifenacin succinate) - Drug Profile 66
  • (glycopyrrolate + rivastigmine) - Drug Profile 68
  • AADvac-1 - Drug Profile 69
  • AD-35 - Drug Profile 71
  • ANAVEX-371 - Drug Profile 72
  • Antibody to Inhibit Tau Proteins for Corticobasal Degeneration - Drug Profile 74
  • Antisense RNAi Oligonucleotide for Cerebral Ischemia and Dementia - Drug Profile 75
  • ASN-561 - Drug Profile 76
  • AZP-2006 - Drug Profile 77
  • BAN-0805 - Drug Profile 79
  • BI-409306 - Drug Profile 80
  • CB-2233 - Drug Profile 82
  • CB-8411 - Drug Profile 83
  • Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile 84
  • choline alfoscerate SR - Drug Profile 85
  • CIDEM-162 - Drug Profile 86
  • D-217 - Drug Profile 87
  • dehydroevodiamine hydrochloride - Drug Profile 88
  • donepezil Depot - Drug Profile 89
  • donepezil Patch - Drug Profile 90
  • dronabinol - Drug Profile 91
  • Drugs for Dementia - Drug Profile 93
  • Drugs to Agonize Hepatocyte Growth Factor Receptor for Dementia - Drug Profile 94
  • Drugs to Inhibit Matrix Metalloproteinase for Dementia and Cognitive Impairment - Drug Profile 95
  • DWJ-1365 - Drug Profile 96
  • E-2027 - Drug Profile 97
  • E-2609 - Drug Profile 98
  • eltoprazine - Drug Profile 101
  • GIBH-130 - Drug Profile 106
  • Gln-1062 - Drug Profile 107
  • GTC-6000 - Drug Profile 110
  • gugulipid - Drug Profile 111
  • HOB-075 - Drug Profile 112
  • HTL-18318 - Drug Profile 113
  • intepirdine - Drug Profile 114
  • INV-331 - Drug Profile 117
  • IRL-752 - Drug Profile 118
  • IW-6463 - Drug Profile 119
  • landipirdine - Drug Profile 120
  • levetiracetam - Drug Profile 122
  • LUAF-20513 - Drug Profile 124
  • MM-201 - Drug Profile 125
  • Monoclonal Antibodies for Alzheimer's Disease and Vascular Dementia - Drug Profile 126
  • Monoclonal Antibodies to Inhibit SORT1 for Alzheimer's Disease and Dementia - Drug Profile 127
  • Monoclonal Antibodies to Inhibit Tau for CNS Disorders - Drug Profile 128
  • Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 129
  • monosodium luminol - Drug Profile 130
  • NAT - Drug Profile 132
  • nelotanserin - Drug Profile 133
  • Neurostem - Drug Profile 135
  • NI-205 - Drug Profile 137
  • NI-308 - Drug Profile 138
  • NNC-269100 - Drug Profile 139
  • NP-001 - Drug Profile 140
  • NPT100-18A - Drug Profile 143
  • NXN-413 - Drug Profile 144
  • NXN-613 - Drug Profile 145
  • ORY-2001 - Drug Profile 146
  • PAM-43 - Drug Profile 149
  • PBT-434 - Drug Profile 150
  • PD-2015 - Drug Profile 152
  • PD-2024 - Drug Profile 153
  • PD-2244 - Drug Profile 154
  • Peptide to Inhibit BACE for Cerebropathy and Dementia - Drug Profile 155
  • PST-900 - Drug Profile 156
  • rivastigmine - Drug Profile 157
  • salicylamine - Drug Profile 158
  • SGE-201 - Drug Profile 159
  • SIN-1502 - Drug Profile 160
  • Small Molecule for Vascular Dementia - Drug Profile 161
  • Small Molecule to Activate ABC Transporter for Neurodegeneration Disorders - Drug Profile 162
  • Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 163
  • Small Molecule to Agonize Dopamine D1 Receptor for Dementia Associated with Alzheimer's Disease - Drug Profile 164
  • Small Molecule to Inhibit Glycogene 5 for Dementia - Drug Profile 165
  • Small Molecule to Inhibit TNF-Alpha for CNS Disorders - Drug Profile 166
  • Small Molecules for Ophthalmology and CNS Disorders - Drug Profile 167
  • Small Molecules to Agonize HGFR for CNS Disorders - Drug Profile 168
  • Small Molecules to Agonize M1 Muscarinic Acetylcholine Receptor for Central Nervous System - Drug Profile 169
  • Small Molecules to Inhibit TANA for ALS, Alzheimer's Disease and Dementia - Drug Profile 170
  • SND-14 - Drug Profile 171
  • Stem Cell Therapy for Dementia Associated with Alzheimer's Disease - Drug Profile 172
  • SUVNI-1307014 - Drug Profile 174
  • SUVNI-1312004 - Drug Profile 175
  • Synthetic Peptides to Activate PACAP Receptor and Antagonize VPAC1, VPAC2 for Neurological Disorders - Drug Profile 176
  • TAK-070 - Drug Profile 177
  • TauC-3 - Drug Profile 178
  • tolfenamic acid - Drug Profile 180
  • TPI-287 - Drug Profile 181
  • TRx-0237 - Drug Profile 185
  • UE-2343 - Drug Profile 189
  • VYTAU-01 - Drug Profile 192
  • WIB-1001C - Drug Profile 193
  • zonisamide - Drug Profile 194
  • Dementia - Dormant Projects 196
  • Dementia - Discontinued Products 200
  • Dementia - Product Development Milestones 201
  • Featured News & Press Releases 201
  • Appendix 212
  • Methodology 212
  • Coverage 212
  • Secondary Research 212
  • Primary Research 212
  • Expert Panel Validation 212
  • Contact Us 212
  • Disclaimer 213

List of Tables

  • Number of Products under Development for Dementia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Dementia - Pipeline by Acorda Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Actinogen Medical Ltd, H1 2017
  • Dementia - Pipeline by Adamas Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by AgeneBio Inc, H1 2017
  • Dementia - Pipeline by Alector LLC, H1 2017
  • Dementia - Pipeline by Allergan Plc, H1 2017
  • Dementia - Pipeline by AlzProtect SAS, H1 2017
  • Dementia - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Dementia - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Dementia - Pipeline by Asceneuron SA, H1 2017
  • Dementia - Pipeline by Axon Neuroscience SE, H1 2017
  • Dementia - Pipeline by Axovant Sciences Ltd., H1 2017
  • Dementia - Pipeline by BioArtic AB, H1 2017
  • Dementia - Pipeline by Biogen Inc, H1 2017
  • Dementia - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Dementia - Pipeline by Cortice Biosciences Inc, H1 2017
  • Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2017
  • Dementia - Pipeline by Eisai Co Ltd, H1 2017
  • Dementia - Pipeline by Eli Lilly and Company, H1 2017
  • Dementia - Pipeline by H. Lundbeck A/S, H1 2017
  • Dementia - Pipeline by Heptares Therapeutics Ltd, H1 2017
  • Dementia - Pipeline by HSRx Group, H1 2017
  • Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Ildong Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Immungenetics AG, H1 2017
  • Dementia - Pipeline by ImStar Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2017
  • Dementia - Pipeline by Intellect Neurosciences Inc, H1 2017
  • Dementia - Pipeline by INVENT Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by M3 Biotechnology Inc, H1 2017
  • Dementia - Pipeline by MediPost Co Ltd, H1 2017
  • Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2017
  • Dementia - Pipeline by Neurimmune Holding AG, H1 2017
  • Dementia - Pipeline by Neuropore Therapies Inc, H1 2017
  • Dementia - Pipeline by NsGene A/S, H1 2017
  • Dementia - Pipeline by Oryzon Genomics SA, H1 2017
  • Dementia - Pipeline by P2D Bioscience, H1 2017
  • Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
  • Dementia - Pipeline by Pharmasum Therapeutics AS, H1 2017
  • Dementia - Pipeline by Prana Biotechnology Ltd, H1 2017
  • Dementia - Pipeline by Sage Therapeutics Inc, H1 2017
  • Dementia - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Stelic Institute & Co Inc, H1 2017
  • Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2017
  • Dementia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Dementia - Pipeline by Suven Life Sciences Ltd, H1 2017
  • Dementia - Pipeline by Sylentis SAU, H1 2017
  • Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2017
  • Dementia - Pipeline by Voyager Therapeutics Inc, H1 2017
  • Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2017
  • Dementia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2017
  • Dementia - Dormant Projects, H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Dementia - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Dementia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Dementia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top